| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM198807073190101 |
| P698 | PubMed publication ID | 3288866 |
| P2093 | author name string | Rosenkranz A | |
| Eibl MM | |||
| Wolf HM | |||
| Fürnkranz H | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | infant feeding | Q50146839 |
| necrotizing enterocolitis | Q10859678 | ||
| P304 | page(s) | 1-7 | |
| P577 | publication date | 1988-07-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding | |
| P478 | volume | 319 |
| Q37817652 | A unifying hypothesis for pathogenesis and prevention of necrotizing enterocolitis |
| Q30300455 | Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants |
| Q41114249 | Appropriate therapeutic use of immunoglobulin |
| Q67958199 | Benefit of oral immune globulin therapy in patients with immunodeficiency and chronic diarrhea |
| Q37972437 | Benefits and risks of IgA in immunoglobulin preparations. |
| Q47297656 | Bovine Colostrum in Prevention of Necrotizing Enterocolitis and Sepsis in Very Low Birth Weight Neonates: A Randomized, Double-blind, Placebo-controlled Pilot Trial |
| Q37036057 | Bovine Lactogenic Immunity Against Pediatric Enteropathogens |
| Q35094381 | Bovine lactogenic immunity against cholera toxin-related enterotoxins and Vibrio cholerae outer membranes |
| Q43176554 | Brisk walking and high density lipoprotein cholesterol |
| Q40423372 | Carbon monoxide protects against the development of experimental necrotizing enterocolitis |
| Q46369339 | Changing trends in necrotizing enterocolitis. Experience with 302 cases in two decades |
| Q38820288 | Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations |
| Q30433993 | Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants |
| Q55248888 | Comparison of Human Milk Immunoglobulin Survival during Gastric Digestion between Preterm and Term Infants. |
| Q34422051 | Cooperativity among secretory IgA, the polymeric immunoglobulin receptor, and the gut microbiota promotes host-microbial mutualism |
| Q37419105 | Current concepts regarding the pathogenesis of necrotizing enterocolitis |
| Q40978173 | Development of immune function in the intestine and its role in neonatal diseases. |
| Q42503895 | Dietary supplementation with ovine serum immunoglobulin attenuates acute effects on growth, organ weights, gut morphology and intestinal mucin production in the growing rat challenged with Salmonella enteritidis. |
| Q64889442 | Differences in Maternal Immunoglobulins within Mother's Own Breast Milk and Donor Breast Milk and across Digestion in Preterm Infants. |
| Q34354519 | Donor human milk for preterm infants |
| Q33754864 | Effects of nutrients in human milk on the recipient premature infant |
| Q74163574 | Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trial |
| Q40694547 | Enteric infectious disease in neonates. Epidemiology, pathogenesis, and a practical approach to evaluation and therapy |
| Q72190293 | Epidemiology of necrotizing enterocolitis |
| Q40694516 | Epidemiology of necrotizing enterocolitis. |
| Q47245834 | Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight |
| Q40983804 | Evaluation of caffeine and the development of necrotizing enterocolitis |
| Q33679837 | Expression of functional immunomodulatory and anti-inflammatory factors in human milk. |
| Q73882494 | Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells |
| Q72730386 | Familial enteropathy with villous edema and immunoglobulin G2 subclass deficiency |
| Q40889720 | Feeding the low birth weight infant. |
| Q35134564 | Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. |
| Q37937205 | Gastrointestinal host defense and necrotizing enterocolitis |
| Q71665018 | Gastrointestinal perforation and peritonitis in infants and children: experience with 179 cases over ten years |
| Q38130882 | Human milk and the premature infant |
| Q77098100 | Immunoglobulin A supplementation abrogates bacterial translocation and preserves the architecture of the intestinal epithelium |
| Q42503979 | Immunomodulatory effects of ovine serum immunoglobulin in the growing rat. |
| Q96773740 | Impact of pertussis-specific IgA, IgM, and IgG antibodies in mother's own breast milk and donor breast milk during preterm infant digestion |
| Q74381949 | In situ delivery of passive immunity by lactobacilli producing single-chain antibodies |
| Q51009069 | Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. |
| Q38188656 | Inflammatory signals that regulate intestinal epithelial renewal, differentiation, migration and cell death: Implications for necrotizing enterocolitis |
| Q50018135 | Intact but not denatured ovine serum immunoglobulins positively modulate mucosal immune mediators in the growing rat challenged with Salmonella enteritidis |
| Q36890371 | Is There a Role for the Enteral Administration of Serum-Derived Immunoglobulins in Human Gastrointestinal Disease and Pediatric Critical Care Nutrition? |
| Q72189085 | Lack of effect of orally administered human serum immunoglobulin on the normal human oral and intestinal microflora |
| Q58712827 | Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections |
| Q46357507 | Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids |
| Q92826466 | Maternal IgA protects against the development of necrotizing enterocolitis in preterm infants |
| Q33781408 | Milk epidermal growth factor and gut protection |
| Q37817647 | Models of the pathogenesis of necrotizing enterocolitis |
| Q38123163 | Multi-faceted functions of secretory IgA at mucosal surfaces |
| Q36507353 | Multi-modal approach to prophylaxis of necrotizing enterocolitis: clinical report and review of literature. |
| Q94551348 | Necrotiserende enterocolitis: samenvatting van de huidige kennis |
| Q36617416 | Necrotising enterocolitis |
| Q44468304 | Necrotising enterocolitis--a community-acquired infectious disease? |
| Q72014082 | Necrotizing enterocolitis |
| Q47635269 | Necrotizing enterocolitis after gastroschisis repair: a preventable complication? |
| Q34032622 | Necrotizing enterocolitis and hematopoietic cytokines |
| Q40694544 | Necrotizing enterocolitis and infection |
| Q40553644 | Necrotizing enterocolitis in premature infants and newborns |
| Q93534104 | Necrotizing enterocolitis mortality in the United States, 1979-85 |
| Q40866248 | Necrotizing enterocolitis. New thoughts about pathogenesis and potential treatments |
| Q37136941 | Necrotizing enterocolitis: a multifactorial disease with no cure |
| Q34538091 | Necrotizing enterocolitis: a practical guide to its prevention and management |
| Q38134474 | Necrotizing enterocolitis: contemporary management and outcomes |
| Q33731534 | Necrotizing enterocolitis: pathophysiology and prevention |
| Q40978132 | Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention |
| Q37760432 | Neonatal Necrotizing Enterocolitis -Inflammation and Intestinal Immaturity |
| Q68588913 | Neonatal necrotizing enterocolitis: bridging the basic science with the clinical disease |
| Q37831865 | New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections |
| Q33964479 | Nursing the preterm surgical neonate |
| Q35139882 | Nutrition in the neonatal intensive care unit: how do we reduce the incidence of extrauterine growth restriction? |
| Q60949695 | Oral Passive Immunization With Plasma-Derived Polyreactive Secretory-Like IgA/M Partially Protects Mice Against Experimental Salmonellosis |
| Q40899595 | Oral delivery of antibodies. Future pharmacokinetic trends |
| Q50303364 | Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study |
| Q24185925 | Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates |
| Q24247424 | Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates |
| Q34424038 | Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth-weight neonates |
| Q36946876 | Oral ingestion of egg yolk immunoglobulin from hens immunized with an enterotoxigenic Escherichia coli strain prevents diarrhea in rabbits challenged with the same strain |
| Q43508799 | Orally administered ovine serum immunoglobulins modulate the intestinal levels of Lactobacillus and enterobacteria in the growing rat. |
| Q33640433 | Passive immunity against human pathogens using bovine antibodies |
| Q33914263 | Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections |
| Q36379240 | Preventing necrotizing enterocolitis by food additives in neonates: A network meta-analysis revealing the efficacy and safety |
| Q36086214 | Prevention of necrotising enterocolitis: year 2004 and beyond |
| Q43473637 | Prevention of necrotizing enterocolitis |
| Q37462104 | Probiotic and prebiotic supplementation for the prevention of neonatal necrotizing enterocolitis |
| Q35205685 | Probiotics for preterm infants? |
| Q36527968 | Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation |
| Q62608042 | Protection of breast-fed infants against Campylobacter diarrhea by antibodies in human milk |
| Q37268603 | Rational principles for immunoglobulin prophylaxis and therapy of neonatal infections. |
| Q35066850 | Risk factors for necrotising enterocolitis: the influence of gestational age |
| Q91908969 | Role of micro-organisms in necrotizing enterocolitis |
| Q95814704 | Rotavirus positive (RV+) and non-rotavirus (RV-) necrotizing enterocolitis (NEC) in 32 infants |
| Q38423920 | Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans |
| Q89236734 | Survival of Immunoglobulins from Human Milk to Preterm Infant Gastric Samples at 1, 2, and 3 h Postprandial |
| Q38323786 | Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. |
| Q67882948 | The Relevance of Immunoglobulin in the Prevention of Necrotizing Enterocolitis |
| Q37677906 | The Role of Mucosal Immunity in the Pathogenesis of Necrotizing Enterocolitis |
| Q91908962 | The epidemiology and pathogenesis of necrotizing enterocolitis |
| Q37210802 | The immunological landscape in necrotising enterocolitis |
| Q33679845 | The use of human milk and breastfeeding in premature infants. |
| Q34173763 | The use of human milk for premature infants |
| Q35682601 | Treatment and prevention of necrotizing enterocolitis |
| Q73226851 | Upper respiratory infections in children: response to endonasal administration of IGA |
| Q33417587 | Use of intravenous gammaglobulin as an immune replacement and an immune suppressant |
| Q33542433 | Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases |
Search more.